Rating Change
Barclays reiterated its Equal-Weight rating on Biogen Inc. (NASDAQ:BIIB) on October 28, 2026.
reiterateNASDAQ:BIIB
Barclays Reiterates Equal-Weight Rating on Biogen Inc. (BIIB)
Barclays reiterated its Equal-Weight rating on Biogen Inc. (NASDAQ:BIIB) on October 28, 2026.
At publication ·
What changed
Biogen Inc. (NASDAQ:BIIB) · reiterate
- Firm
- Barclays
- Rating
- Equal-Weight to Equal-Weight
- Price at event
- $244.05
- Market capitalization
- $25.3B
At a glance
Key takeaways
- Barclays maintained an Equal-Weight rating on Biogen (BIIB) on October 28, 2026, suggesting the stock is fairly valued with limited upside or downside.
Market Context
Biogen Inc. operates in the Healthcare sector. The stock currently trades at $244.05 with a market capitalization of $25.3B. The stock has gained 39.8% over the past 52 weeks.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Biogen Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Biogen Inc.
Among the 10 most recent ratings: 7 Buy, 2 Hold, 1 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Oct 28, 2026 | Barclays | Equal-Weight | N/A |
| Oct 22, 2026 | B of A Securities | Neutral | N/A |
| Oct 21, 2026 | TD Cowen | Buy | N/A |
| Oct 20, 2026 | Wells Fargo | Overweight | N/A |
| Oct 12, 2026 | JP Morgan | Overweight | N/A |
Related Tools: Analyst Ratings Dashboard | View BIIB Stock Page
Frequently Asked Questions
What does the Equal-Weight rating mean for BIIB?
A rating of Equal-Weight from Barclays reflects the analyst's outlook on Biogen Inc. (NASDAQ:BIIB). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the BIIB forecast page.
